Lake Street Reiterates Buy Rating on Harrow, Increases Price Target to $70
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 29 2025
0mins
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HROW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HROW
Wall Street analysts forecast HROW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HROW is 72.40 USD with a low forecast of 63.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 41.930
Low
63.00
Averages
72.40
High
94.00
Current: 41.930
Low
63.00
Averages
72.40
High
94.00
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Okta Inc (OKTA) Options Volume Hits 13,284 Contracts, 52.9% of Average Daily Volume
- Active Options Trading: Okta Inc's options volume today reached 13,284 contracts, equivalent to approximately 1.3 million shares, indicating robust activity in the options market, with this volume representing 52.9% of its average daily trading volume of 2.5 million shares over the past month.
- High Volume Insights: Notably, the $91 strike put option has seen significant trading, with 1,939 contracts exchanged today, representing about 193,900 underlying shares, reflecting market attention at this price level and potential risk management strategies.
- Harrow Inc Options Activity: Concurrently, Harrow Inc recorded an options volume of 3,058 contracts, equivalent to approximately 305,800 shares, which is about 52.6% of its average daily trading volume of 581,730 shares over the past month, indicating relative activity in its options market.
- Bullish Call Options Trend: The $55 strike call option for Harrow Inc also attracted attention, with a trading volume of 1,106 contracts today, representing around 110,600 underlying shares, suggesting investor optimism regarding the company's future performance.
Continue Reading
Antero Resources Sees 31,767 Options Contracts Trading, 64.9% of Average Volume
- Active Options Trading: Antero Resources Corp (AR) recorded an options trading volume of 31,767 contracts today, equating to approximately 3.2 million shares, which represents 64.9% of its average daily trading volume of 4.9 million shares over the past month, indicating a significant increase in market interest in the stock.
- Put Option Concentration: Notably, the $28 strike put option expiring on February 20, 2026, saw a trading volume of 23,642 contracts today, representing about 2.4 million underlying shares, reflecting heightened investor expectations for potential downward price movement in the future.
- Shift4 Payments Options Activity: Shift4 Payments Inc (FOUR) has seen an options trading volume of 9,949 contracts today, equivalent to approximately 994,900 shares, which also constitutes 64.9% of its average daily trading volume of 1.5 million shares over the past month, showcasing the stock's active market engagement.
- Call Option Trading: The $65 strike call option for FOUR recorded a trading volume of 4,127 contracts today, representing around 412,700 underlying shares, indicating increased investor confidence in the stock's potential for upward movement, which may influence its short-term price trajectory.
Continue Reading